AngioDynamics Net Worth
AngioDynamics Net Worth Breakdown | ANGO |
AngioDynamics Net Worth Analysis
AngioDynamics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including AngioDynamics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of AngioDynamics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform AngioDynamics' net worth analysis. One common approach is to calculate AngioDynamics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares AngioDynamics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing AngioDynamics' net worth. This approach calculates the present value of AngioDynamics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of AngioDynamics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate AngioDynamics' net worth. This involves comparing AngioDynamics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into AngioDynamics' net worth relative to its peers.
Enterprise Value |
|
To determine if AngioDynamics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AngioDynamics' net worth research are outlined below:
| AngioDynamics generated a negative expected return over the last 90 days | |
| AngioDynamics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 303.91 M. Net Loss for the year was (184.35 M) with profit before overhead, payroll, taxes, and interest of 174.25 M. | |
| AngioDynamics currently holds about 24.56 M in cash with (28.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31. | |
| AngioDynamics has a poor financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: DexCom and OURA Ink Partnership for Metabolic Health Innovation |
AngioDynamics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AngioDynamics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AngioDynamics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 10th of July 2024 Next Financial Report | View | |
| 29th of February 2024 Next Fiscal Quarter End | View | |
| 10th of July 2024 Next Fiscal Year End | View | |
| 30th of November 2023 Last Quarter Report | View | |
| 31st of May 2023 Last Financial Announcement | View |
Know AngioDynamics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AngioDynamics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AngioDynamics backward and forwards among themselves. AngioDynamics' institutional investor refers to the entity that pools money to purchase AngioDynamics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 896.6 K | State Street Corp | 2024-06-30 | 789.2 K | Kent Lake Capital Llc | 2024-06-30 | 750 K | Two Sigma Advisers, Llc | 2024-06-30 | 568.7 K | Paradigm Capital Management, Inc. | 2024-06-30 | 478 K | Jpmorgan Chase & Co | 2024-06-30 | 429.9 K | Assenagon Asset Management Sa | 2024-09-30 | 425.1 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 414.1 K | Acuitas Investments, Llc | 2024-09-30 | 403.3 K | Blackrock Inc | 2024-06-30 | 4.6 M | Systematic Financial Management Lp | 2024-09-30 | 2.4 M |
Follow AngioDynamics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 277.53 M.Market Cap |
|
Project AngioDynamics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.73) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.58) | (0.55) | |
| Return On Equity | (0.90) | (0.85) |
When accessing AngioDynamics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures AngioDynamics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AngioDynamics' profitability and make more informed investment decisions.
Evaluate AngioDynamics' management efficiency
AngioDynamics has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7785) %, meaning that it created substantial loss on money invested by shareholders. AngioDynamics' management efficiency ratios could be used to measure how well AngioDynamics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to grow to -0.73. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, AngioDynamics' Debt To Assets are very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.12 | 9.51 | |
| Tangible Book Value Per Share | 3.19 | 3.19 | |
| Enterprise Value Over EBITDA | (12.83) | (12.19) | |
| Price Book Value Ratio | 1.23 | 1.29 | |
| Enterprise Value Multiple | (12.83) | (12.19) | |
| Price Fair Value | 1.23 | 1.29 | |
| Enterprise Value | 183.4 M | 335.7 M |
At AngioDynamics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 0.7766 | Revenue 292.7 M | Quarterly Revenue Growth (0.14) | Revenue Per Share 7.249 | Return On Equity (0.78) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AngioDynamics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AngioDynamics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AngioDynamics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AngioDynamics Corporate Filings
8K | 15th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 10th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 26th of September 2024 Other Reports | ViewVerify |
AngioDynamics Earnings per Share Projection vs Actual
Already Invested in AngioDynamics?
The danger of trading AngioDynamics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AngioDynamics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AngioDynamics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AngioDynamics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AngioDynamics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AngioDynamics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Angiodynamics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Angiodynamics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 7.249 | Quarterly Revenue Growth (0.14) | Return On Assets (0.06) | Return On Equity (0.78) |
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.